Barrett's esophagus represents a premalignant condition, which is strongly associated with
the incidence of esophageal adenocarcinoma. Currently, there are no validated markers to …

The rising incidence of esophageal adenocarcinoma has focused attention on the only
known risk factor: Barrett's esophagus. Practice guidelines for the diagnosis, surveillance …

This article reviews methods to minimize the complications associated with endoscopic
therapy for patients with Barrett's esophagus. To place this discussion in context, the natural …

The standard of care for treatment of Barrett's esophagus (BE) with early esophageal
neoplasia, including high-grade dysplasia (HGD) and intramucosal adenocarcinoma (IMC) …

Barrett's esophagus (BE) is a premalignant condition that predisposes patients to
esophageal adenocarcinoma. This risk increases with increasing dysplasia, especially in …

Esophageal adenocarcinoma is the most rapidly increasing cancer in western countries.
High-grade dysplasia (HGD) arising from Barrett's esophagus (BE) is the most important risk …

In the last 5–10 years, endoscopic ablative therapies have been gaining ground as
treatment for Barrett's esophagus associated with high-grade dysplasia and early cancer …

Barrett's esophagus (BE) is a premalignant lesion known to sequentially progress to
esophageal adenocarcinoma. Management of BE has changed significantly over the last 5 …

Barrett's esophagus is a premalignant metaplastic process that involves the distal
esophagus and requires lifelong surveillance and treatment. One of the major risk factors …

Barrett's esophagus is the condition in which a metaplastic columnar epithelium replaces the
stratified squamous epithelium that normally lines the distal esophagus. The condition …